AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026
Two abstracts on long-term follow-up data of AHB-137 treatment for chronic hepatitis B have been selected for late-breaking oral presentations at The Liver Meeting® 2026. SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together,...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.